Eagle Pharmaceuticals, Inc.

Privately held Neurogastrx thinks it has a potential blockbuster with a Phase II candidate that can reduce the nausea and vomiting associated with GLP-1 therapies for obesity, type 2 diabetes and othe

Eagle Pharmaceuticals has for now averted the impending suspension and removal of its shares from the Nasdaq Capital Market list after earlier being pulled up by the stock exchange for failure to tim

After approving seven novel agents in June, the US FDA may be able to relax a little in July. The coming month features a handful of novel agents, new formulations, and an OTC product among fewer than

Following a lengthy legal battle, which included an ‘at-risk’ launch with litigation still hanging over, Eagle Pharmaceuticals, Inc. has withdrawn its generic version of Endo’s Vasostrict (vasopress